{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:42:56Z","timestamp":1778892176340,"version":"3.51.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Febrile neutropenia (FN) is a recognised adverse event associated with chemotherapy. This study investigates the impact of atezolizumab, an immune checkpoint inhibitor, on the incidence of FN in patients with non-small cell lung cancer receiving concurrent chemotherapy in Japan.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This post-marketing database study was conducted using data from patients with non-small cell lung cancer provided by Medical Data Vision Co., Ltd. covering April 2008 to present. The primary outcome measured was FN incidence, and its causal association with atezolizumab use was examined by comparing the atezolizumab plus bevacizumab plus carboplatin plus paclitaxel [ABCP])-containing regimen to the BCP control group. The data period was from 1 September, 2015, to 31 December, 2021, including approval date of this drug, 21 December, 2018.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The database identified 301 subjects for the ABCP regimen (exposure) group, 44 for the BCP regimen (cohort design control) group during the same period, and 207 for BCP regimen (historical cohort design control) group before the approval of atezolizumab. For historical cohort design, the incidence and adjusted incidence ratios of febrile neutropenia in the exposure group to the control group were 6.13 (95% CI 2.78\u201313.49) and 8.19 (95% CI 3.79\u201325.33), respectively. Sensitivity analysis showed FN occurred in 17% (52\/301) of the exposure group, 4.5% (2\/44) of the cohort design control group, and 3% (7\/207) of the historical cohort design control group.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The incidence of FN was higher in the exposure group. Considering the study results, special caution is needed for FN occurrence in patients receiving atezolizumab.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s10147-024-02669-y","type":"journal-article","created":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T03:38:38Z","timestamp":1734320318000},"page":"298-308","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Evaluating the impact of atezolizumab on febrile neutropenia occurrence in patients with NSCLC undergoing chemotherapy in Japan: a real-world post-marketing database study"],"prefix":"10.1007","volume":"30","author":[{"given":"Sayuri","family":"Nakane","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akinori","family":"Yuri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Miyano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kana","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika","family":"Nakatsuji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuki","family":"Takei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Igarashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryousuke","family":"Harada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,16]]},"reference":[{"issue":"6","key":"2669_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394\u2013424","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"2669_CR2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.5114\/wo.2021.103829","volume":"25","author":"KC Thandra","year":"2021","unstructured":"Thandra KC, Barsouk A, Saginala K et al (2021) Epidemiology of lung cancer. Contemp Oncol\/Wsp\u00f3\u0142czesna Onkologia 25(1):45\u201352","journal-title":"Contemp Oncol\/Wsp\u00f3\u0142czesna Onkologia"},{"key":"2669_CR3","doi-asserted-by":"publisher","first-page":"1090623","DOI":"10.3389\/fpubh.2023.1090623","volume":"11","author":"Y Xia","year":"2023","unstructured":"Xia Y, Chen Y, Chen J et al (2023) Measuring direct non-medical burden among patients with advanced non-small cell lung cancer in China: is there a difference in health status? Front Public Health 11:1090623","journal-title":"Front Public Health"},{"issue":"6","key":"2669_CR4","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.3390\/cancers14061400","volume":"14","author":"PW Simon Garinet","year":"2022","unstructured":"Simon Garinet PW, Mansuet-Lupo A, Fournel L et al (2022) Updated prognostic factors in localized NSCLC. Cancer 14(6):1400","journal-title":"Cancer"},{"key":"2669_CR5","unstructured":"American Cancer Society, Lung Cancer Survival Rates, https:\/\/www.cancer.org\/cancer\/types\/lung-cancer\/detection-diagnosis-staging\/survival-rates.html. 2023"},{"issue":"4","key":"2669_CR6","first-page":"228","volume":"43","author":"AJ Lucas","year":"2018","unstructured":"Lucas AJ, Olin JL, Coleman MD (2018) Management and preventive measures for febrile neutropenia. Pharm Therapeut 43(4):228","journal-title":"Pharm Therapeut"},{"key":"2669_CR7","unstructured":"Punnapuzha S, Edemobi PK, Elmoheen A (2023) Febrile neutropenia. StatPearls Publishing"},{"key":"2669_CR8","doi-asserted-by":"crossref","unstructured":"Nordvig J, Aagaard T, Daugaard G et al. (eds) (2018) Febrile neutropenia and long-term risk of infection among patients treated with chemotherapy for malignant diseases. In: Open forum infectious diseases. Oxford University Press US, Oxford","DOI":"10.1093\/ofid\/ofy255"},{"key":"2669_CR9","doi-asserted-by":"publisher","first-page":"1163971","DOI":"10.3389\/fphar.2023.1163971","volume":"14","author":"J Hou","year":"2023","unstructured":"Hou J, Xie R, Zhang Z et al (2023) Hematologic side effects of immune checkpoint inhibitor with or without chemotherapy in patients with advanced and metastatic gastrointestinal cancer: a systematic review and network meta-analysis of phase 3 trials. Front Pharmacol 14:1163971","journal-title":"Front Pharmacol"},{"issue":"5","key":"2669_CR10","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.cllc.2020.05.008","volume":"21","author":"AC Chiang","year":"2020","unstructured":"Chiang AC, Sequist LVD, Gilbert J et al (2020) Clinical activity and safety of atezolizumab in a phase 1 study of patients with relapsed\/refractory small-cell lung cancer. Clin Lung Cancer 21(5):455-63e4","journal-title":"Clin Lung Cancer"},{"key":"2669_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.666909","volume":"12","author":"D-N Li","year":"2021","unstructured":"Li D-N, Lu W-Q, Yang B-W et al (2021) Atezolizumab monotherapy or plus chemotherapy in first-line treatment for advanced non-small cell lung cancer patients: a meta-analysis. Front Immunol 12:666909","journal-title":"Front Immunol"},{"issue":"24","key":"2669_CR12","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","volume":"378","author":"MA Socinski","year":"2018","unstructured":"Socinski MA, Jotte RM, Cappuzzo F et al (2018) Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med 378(24):2288\u20132301","journal-title":"N Engl J Med"},{"issue":"1","key":"2669_CR13","first-page":"372","volume":"16","author":"R Kanno","year":"2023","unstructured":"Kanno R, Saito Y, Takekuma Y et al (2023) Temporary severe neutropenia during administration of atezolizumab: a novel case report. Case Rep Oncol 16(1):372\u2013377","journal-title":"Case Rep Oncol"},{"key":"2669_CR14","volume":"33","author":"K Seguchi","year":"2021","unstructured":"Seguchi K, Nakashima K, Terao T et al (2021) Febrile neutropenia in a patient with non-small-cell lung cancer treated with atezolizumab: a case report. Respir Med Case Rep 33:101439","journal-title":"Respir Med Case Rep"},{"key":"2669_CR15","unstructured":"Survey of Japanese databases in Japan available for clinical\/pharmaco- epidemiology, information obtained from survey answers as of August 2023), JSPE_DB_TF_J. https:\/\/www.jspe.jp\/mt-static\/FileUpload\/files\/JSPE_DB_TF_E.pdf 2023, August. Available from: https:\/\/www.jspe.jp\/mt-static\/FileUpload\/files\/JSPE_DB_TF_E.pdf."},{"key":"2669_CR16","unstructured":"(eds) JSoCO. Febrile Neutropenia (FN) Treatment Guidelines, Revised 3rd Edition [Electronic version]. 2024."},{"key":"2669_CR17","unstructured":"Care JCFQH. Guidelines for the treatment of febrile neutropenia (FN) (Revised 2nd Edition) Infection Control During Cancer Chemotherapy. 2024"},{"issue":"4","key":"2669_CR18","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1177\/08445621221107108","volume":"54","author":"FI Mowbray","year":"2022","unstructured":"Mowbray FI, Manlongat D, Shukla M (2022) Sensitivity analysis: a method to promote certainty and transparency in nursing and health research. Can J Nurs Res 54(4):371\u2013376","journal-title":"Can J Nurs Res"},{"issue":"17","key":"2669_CR19","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1200\/JCO.21.00306","volume":"39","author":"KN Moore","year":"2021","unstructured":"Moore KN, Bookman M, Sehouli J et al (2021) Atezolizumab, bevacizumab, and chemotherapy for newly diagnosed stage III or IV ovarian cancer: placebo-controlled randomized phase III trial (IMagyn050\/GOG 3015\/ENGOT-OV39). J Clin Oncol 39(17):1842","journal-title":"J Clin Oncol"},{"issue":"4","key":"2669_CR20","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1358\/dot.2017.53.4.2589163","volume":"53","author":"A Krishnamurthy","year":"2017","unstructured":"Krishnamurthy A, Jimeno A (2017) Atezolizumab: a novel PD-L1 inhibitor in cancer therapy with a focus in bladder and non-small cell lung cancers. Drugs Today (Barcelona, Spain: 1998). 53(4):217\u2013237","journal-title":"Drugs Today (Barcelona, Spain: 1998)."},{"key":"2669_CR21","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ejca.2018.07.129","volume":"103","author":"F Petrelli","year":"2018","unstructured":"Petrelli F, Ardito R, Borgonovo K et al (2018) Haematological toxicities with immunotherapy in patients with cancer: a systematic review and meta-analysis. Eur J Cancer 103:7\u201316","journal-title":"Eur J Cancer"},{"key":"2669_CR22","unstructured":"PMDA. Pharmaceuticals and Medical Devices Agency\u2014PMDA https:\/\/www.info.pmda.go.jp\/go\/pack\/4291441A1024_1_15\/?view=frame&style=XML&lang=ja 2022, May. Available from: https:\/\/www.info.pmda.go.jp\/go\/pack\/4291441A1024_1_15\/?view=frame&style=XML&lang=ja"},{"issue":"9","key":"2669_CR23","doi-asserted-by":"publisher","first-page":"3520","DOI":"10.1007\/s12325-024-02921-x","volume":"41","author":"A Hata","year":"2024","unstructured":"Hata A, Iwasawa S, Sasaki Y et al (2024) A DPC database study on the safety of atezolizumab\/bevacizumab\/carboplatin\/paclitaxel in non-small cell lung cancer in Japanese patients. Adv Ther 41(9):3520\u20133538","journal-title":"Adv Ther"},{"issue":"3","key":"2669_CR24","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1001\/jamaoncol.2023.5258","volume":"10","author":"Y Shiraishi","year":"2024","unstructured":"Shiraishi Y, Kishimoto J, Sugawara S et al (2024) Atezolizumab and platinum plus pemetrexed with or without bevacizumab for metastatic nonsquamous non-small cell lung cancer: a phase 3 randomized clinical trial. JAMA Oncol 10(3):315\u2013324","journal-title":"JAMA Oncol"},{"key":"2669_CR25","doi-asserted-by":"publisher","first-page":"107843","DOI":"10.1016\/j.lungcan.2024.107843","volume":"193","author":"L Amari","year":"2024","unstructured":"Amari L, Tomasini P, Dantony E et al (2024) Safety and Patient-Reported outcomes of atezolizumab plus chemotherapy with or without bevacizumab in stage IIIB\/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies (GFPC 06-018 study). Lung Cancer 193:107843","journal-title":"Lung Cancer"},{"issue":"6","key":"2669_CR26","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.21873\/anticanres.17072","volume":"44","author":"K Endo","year":"2024","unstructured":"Endo K, Tanaka H, Matsuo H et al (2024) Adverse event profile of atezolizumab, bevacizumab, carboplatin, and paclitaxel combination therapy based on JADER. Anticancer Res 44(6):2653\u20132660","journal-title":"Anticancer Res"},{"key":"2669_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.765608","volume":"11","author":"A Zaremba","year":"2021","unstructured":"Zaremba A, Kramer R, De Temple V et al (2021) Grade 4 neutropenia secondary to immune checkpoint inhibition\u2014a descriptive observational retrospective multicenter analysis. Front Oncol 11:765608","journal-title":"Front Oncol"},{"issue":"10","key":"2669_CR28","doi-asserted-by":"publisher","first-page":"9114","DOI":"10.18632\/oncotarget.24148","volume":"9","author":"K Tecza","year":"2018","unstructured":"Tecza K, Pamula-Pilat J, Lanuszewska J et al (2018) Pharmacogenetics of toxicity of 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients. Oncotarget 9(10):9114","journal-title":"Oncotarget"},{"key":"2669_CR29","unstructured":"Fever Neutropenia (FN) treatment guidelines, 2nd revised edition: infection control during cancer chemotherapy. Japan Society of Clinical Oncology."}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-024-02669-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-024-02669-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-024-02669-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T11:56:36Z","timestamp":1738324596000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-024-02669-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,16]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["2669"],"URL":"https:\/\/doi.org\/10.1007\/s10147-024-02669-y","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,16]]},"assertion":[{"value":"24 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the authors are employees of Chugai Pharmaceutical Co., Ltd. and have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}